Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01356498 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout
A Phase 3 study of Gout, sponsored by Savient Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
- 20
- Study locations
NCT01356498 is a Phase 3 study of Gout that has completed, run by Savient Pharmaceuticals. The registered enrollment target is 151 participants, below the 8,884-participant average among 34 other Gout trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT01356498, a Phase 3 study of Gout, has completed, sponsored by Savient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies and obtain long-term safety and efficacy data.
Conditions Studied
Interventions
- BIOLOGICAL pegloticase
Study Locations (20)
Ohio
- New Horizons Clinical Research - Cincinnati
- The Ohio State University - Columbus
- STAT Research, Inc. - Dayton
- David R. Mandel, MD, Inc. - Mayfield Village
California
- Kaiser Permanente Medical Center, Clinical Trials Unit - San Francisco
- Pacific Arthritis Center Medical Group - Santa Maria
- Agilence Arthritis & Osteoporosis Medical Center - Whittier
Florida
- Arthritis & Rheumatic Disease Specialties - Aventura
- Ocala Rheumatology Research Center - Ocala
- St. Petersburg Arthritis Center - St. Petersburg
Maryland
- Peter A. Holt, M.D. - Baltimore
- Center for Rheumatology and Bone Research - Wheaton
District of Columbia
- Veterans Affairs Medical Center - Washington D.C.
Illinois
- The University of Chicago - Chicago
Kentucky
- Graves Gilbert Clinic - Bowling Green
Michigan
- Justus J. Fiechtner, MD, PC - Lansing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01356498
The ClinicalTrials.gov registry entry for NCT01356498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,884-participant average among 34 other Gout trials with a reported enrollment target (98% lower). The listed sponsor is Savient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gout appearing as the primary indexed condition, and to 1 intervention - of which pegloticase is the first listed.
NCT01356498 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Ohio, California, Florida.
Frequently Asked Questions
What is clinical trial NCT01356498 about?
NCT01356498 is a clinical study titled "Open-Label Extension Study for Patients Who Completed a Phase 3 Double-blind Study of PEG-uricase for Symptomatic Gout". This is an open-label extension phase of two double-blind, placebo-controled Phase 3 protocols evaluating PEG-uricase in the treatment of hyperuricemic subjects with symptomatic gout. The purpose of this study is to provide a continuation of treatment to subjects completing the double-blind studies ...
What is the current status of trial NCT01356498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2006-12. Estimated completion is 2010-01.
What conditions does trial NCT01356498 study?
This clinical trial studies the following conditions: Gout.
What interventions are being tested in trial NCT01356498?
The interventions under investigation include: pegloticase (BIOLOGICAL).
Who is sponsoring clinical trial NCT01356498?
This trial is sponsored by Savient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01356498 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gout
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Dotinurad Versus Allopurinol in Participants With Gout
RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
COMPLETED · Phase 3
-
Combining Lesinurad With Allopurinol in Inadequate Responders
COMPLETED · Phase 3
-
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.